Exercise Loading Biology Post-Traumatic OsteoArthritis Study - a Pilot and Feasibility Study
Launched by MAY ARNA RISBERG · Mar 21, 2025
Trial Information
Current as of May 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The main risk factors for knee OA disease are well-known: joint injuries and obesity. For those with ACL injury, systematic reviews have reported between 4 to 6 times increased risk of developing OA after ACL injury (PTOA). The following risk factors have been identified for PTOA in a recent systematic review by our OPTIKNEE group: ACL injury with concomitant injuries (meniscus and cartilage injuries), re-injuries after ACL injury, long-lasting quadriceps dysfunction, and inflammation after joint injury.
A better understanding of mechanisms to stratify the patients into different subgroups...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Unilateral ACL injury and ACLR (≤ one year between injury and surgery)
- • Surgery performed using the BPTB or hamstring grafts
- • Age between 16 and 40 years
- • Isolated ACL or with concomitant meniscal injury/cartilage injuries at surgery
- • Location (living) in the Oslo or Viken areas (due to the need for testing performed at the Norwegian School of Sport Sciences and Oslo University Hospital)
- • Healthy, uninjured contralateral knee
- Exclusion Criteria:
- • Above 40 years and below 16 years of age
- • Previous ACL injury (re-rupture of graft or an ACL injury more than one year between injury and surgery)
- • MCL/LCL grade 3 injuries
- • Other lower extremity injuries less than one year before inclusion, or previous inflammatory arthropathy or systemic infection or inflammation
- • Participants with bilateral ACL injuries
About May Arna Risberg
May Arna Risberg is a dedicated clinical trial sponsor focused on advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a commitment to rigorous scientific standards and ethical practices, the organization actively collaborates with healthcare professionals and research institutions to design and conduct clinical trials across various therapeutic areas. By fostering a culture of transparency and collaboration, May Arna Risberg aims to accelerate the development of new treatments, ultimately enhancing the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oslo, , Norway
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported